切除修复交叉互补基因1与肿瘤的关系研究进展
摘要
核苷酸切除修复交叉互补基因1(ERCC1)是核苷酸修复系统的重要途径之一,ERCC1基因发生突变可导致ERCC1 mRNA和ERCC1蛋白表达水平发生异常,异常激活核酸修复过程,导致正常细胞发生恶性转化、促进肿瘤的发生发展,并促进恶性肿瘤患者对化疗药物产生耐药性。本文对ERCC1基因多态性、ERCC1 mRNA表达和ERCC1蛋白表达水平与消化、呼吸、血液、生殖等系统肿瘤的发生发展、铂类化疗药物的敏感性、预后等关系进行综述。
引文
[1] Wang B, Xu Q, Yang HW, et al. The association of six polymorphisms of five genes involved in three steps of nucleotide excision repair pathways with hepatocellular cancer risk[J]. Oncotarget, 2016, 7(15):20357-20367.
[2] Li Y, Ou C, Shu H, et al. The ERCC1-4533/8092, TNF-alpha 238/308 polymorphisms and the risk of hepatocellular carcinoma in Guangxi Zhuang populations of China:casecontrol study[J]. Medicine(Baltimore), 2016, 95(44):e5217.
[3]郑霄雁.修复基因ERCC1多态性与肝癌易感性的关系[D].福州:福建医科大学, 2008.
[4] Andrieux LO, Fautrel A, Bessard A, et al. GATA-1 is essential in EGF-mediated induction of nucleotide excision repair activity and ERCC1 expression through ERK2 in human hepatoma cells[J]. Cancer Res, 2007, 67(5):2114-2123.
[5] Wang XC, Wang F, Quan QQ. Roles of XRCC1/XPD/ERCC1 polymorphisms in predicting prognosis of hepatocellular carcinoma in patients receiving transcatheter arterial chemoembolization[J]. Genet Test Mol Biomarkers, 2016, 20(4):176-184.
[6]师怡,陈刚,林贤东,等. ERCC1基因多态性与胃癌发生发展的关系[J].中国肿瘤临床, 2012, 39(13):907-910.
[7] Mo J, Luo M, Cui J, et al. Prognostic value of ERCC1 and ERCC2 gene polymorphisms in patients with gastric cancer receiving platinum-based chemotherapy[J]. Int J Clin Exp Pathol, 2015, 8(11):15065-15071.
[8] Huang J, Hu H, Xie Y, et al. Effect of TUBB3, TS and ERCC1 mRNA expression on chemoresponse and clinical outcome of advanced gastric cancer by multiplex branchedDNA liquid chip technology[J]. Zhong Nan Da Xue Xue Bao Yi Xue Ban, 2013, 38(6):582-589.
[9]黄朝晖,华东,李莉华,等. ERCC1 mRNA表达及基因多态性对胃癌辅助化疗预后的影响[J].南京医科大学学报(自然科学版), 2008, 28(4):453-456.
[10]胡传朋,顾康生. ERCC1蛋白表达在晚期胃癌含铂一线及替吉奥维持治疗中的作用[J].安徽医科大学学报,2016, 51(10):1504-1508.
[11]樊青霞,邢国臣,吴欣爱,等.化疗前食管癌组织中ERCC1 mRNA检测对化疗疗效的预测价值[J].郑州大学学报(医学版), 2005, 40(1):65-67.
[12]周健,吴列. ERCC1蛋白表达及其基因多态性与食管鳞状上皮细胞癌患者生存期关系[J].中国公共卫生, 2016,32(10):1418-1421.
[13] Geva R, Shamai S, Brazowsky E, et al. The predictive role of ERCC1 status in oxaliplatin based neoadjuvant therapy for metastatic colorectal cancer(mCRC)to the liver[J].Cancer Invest, 2015, 33(4):89-97.
[14]李兴普. ERCC1和XRCC1 SNP与结直肠癌易感性、药物敏感性及预后分析[D].泸州:四川医科大学, 2015.
[15]苏国兰. ERCC1蛋白在非霍奇金淋巴瘤组织中的表达及其临床意义[D].南宁:广西医科大学, 2011.
[16]许英君,刘艳艳,姚志华,等. ercc1、rrm1基因在侵袭性非霍奇金淋巴瘤中的表达及临床意义[J].肿瘤防治研究,2013, 40(5):451-454.
[17]王思力,李悦玮,许现辉,等.儿童急性淋巴细胞白血病ERCC1基因多态性分析[J].吉林大学学报(医学版),2007, 33(4):730-733.
[18] Doherty JA, Weiss NS, Fish S, et al. Polymorphisms in nucleotide excision repair genes and endometrial cancer risk[J]. Cancer Epidemiol Biomarkers Prev, 2011, 20(9):1873-1882.
[19] Palomba G, Atzori F, Budroni M, et al. ERCC1 polymorphisms as prognostic markers in T4 breast cancer patients treated with platinum-based chemotherapy[J]. J Transl Med, 2014, 12:272.
[20]齐冰丽,李琰,王娜,等. ERCC1基因多态性与卵巢上皮性癌患者铂类药物化疗敏感性及预后的关系[J].中华妇产科杂志, 2013, 48(11):847-852.
[21]蒋胜,李力,张玮,等. ERCC1基因mRNA表达水平在卵巢上皮性癌组织中的意义[J].实用妇产科杂志, 2009, 25(11):661-663.
[22]田美玲. ERCC1基因多态性及蛋白表达与上皮性卵巢癌铂类化疗敏感性及预后关系的研究[D].石家庄:河北医科大学, 2015.
[23] Cubukcu E, Fatih Olmez O, Saraydaroglu O, et al. Immunohistochemical expression of excision repair cross-complementing 1(ERCC1)in non-small-cell lung cancer:implications for patient outcome[J]. Clin Transl Oncol, 2011,13(11):826-830.
[24]高志强,韩宝惠,沈策,等. ERCC1蛋白检测指导晚期非小细胞肺癌个体化治疗的临床研究[J].中国癌症杂志,2013, 23(5):328-333.
[25] Lee SY, Hong MJ, Jeon HS, et al. Functional intronic ERCC1 polymorphism from regulomeDB can predict survival in lung cancer after surgery[J]. oncotarget, 2015, 6(27):24522-24532.
[26] Takenaka T, Yano T, Kiyohara C, et al. Effects of excision repair cross-complementation group 1(ERCC1)single nucleotide polymorphisms on the prognosis of non-small cell lung cancer patients[J]. Lung Cancer, 2010, 67(1):101-107.
[27] Wei HB, Hu J, Shang LH, et al. A meta-analytic review of ERCC1/MDR polymorphism and chemosensitivity to platinum in patients cell lung cancer1 with advanced nonsmall cell lung cancer[J]. Chin Med J(Engl), 2012, 125(16):2902-2907.
[28]庄琰,张中冕,程留奇. APE1和ERCC1基因多态性和肺腺癌易感性关系研究[J].医药论坛杂志, 2014, 35(5):4-6.
[29]田声望,李惠,谢玲,等.肺癌ERCC1调控区基因多态性与mRNA定量表达关联分析[J].临床肿瘤学杂志, 2009,14(12):1073-1076.
[30] De Castro G Jr, Pasini FS, Siqueira SA, et al. ERCC1 protein, mRNA expression and T19007C polymorphism as prognostic markers in head and neck squamous cell carcinoma patients treated with surgery and adjuvant cisplatinbased chemoradiation[J]. Oncol Rep, 2011, 25(3):693-699.
[31] Gao R, Reece KM, Sissung T. Are race-specific ERCC1haplotypes in melanoma cases versus controls related to the predictive and prognostic value of ERCC1 N118N?[J].BMJ Open, 2013, 3(1):1-7.
[32] Sun Y, Wu Y, Li W, et al. Genetic polymorphisms in nucleotide excision repair pathway influences response to chemotherapy and overall survival in osteosarcoma[J]. Int J Clin Exp Pathol, 2015, 8(7):7905-7912.
[33] Deng XD, Gao Q, Zhang W, et al. The age-related expression decline of ERCC1 and XPF for forensic age estimation:a preliminary study[J]. J Forensic Leg Med, 2017,49:15-19.
[2] Li Y, Ou C, Shu H, et al. The ERCC1-4533/8092, TNF-alpha 238/308 polymorphisms and the risk of hepatocellular carcinoma in Guangxi Zhuang populations of China:casecontrol study[J]. Medicine(Baltimore), 2016, 95(44):e5217.
[3]郑霄雁.修复基因ERCC1多态性与肝癌易感性的关系[D].福州:福建医科大学, 2008.
[4] Andrieux LO, Fautrel A, Bessard A, et al. GATA-1 is essential in EGF-mediated induction of nucleotide excision repair activity and ERCC1 expression through ERK2 in human hepatoma cells[J]. Cancer Res, 2007, 67(5):2114-2123.
[5] Wang XC, Wang F, Quan QQ. Roles of XRCC1/XPD/ERCC1 polymorphisms in predicting prognosis of hepatocellular carcinoma in patients receiving transcatheter arterial chemoembolization[J]. Genet Test Mol Biomarkers, 2016, 20(4):176-184.
[6]师怡,陈刚,林贤东,等. ERCC1基因多态性与胃癌发生发展的关系[J].中国肿瘤临床, 2012, 39(13):907-910.
[7] Mo J, Luo M, Cui J, et al. Prognostic value of ERCC1 and ERCC2 gene polymorphisms in patients with gastric cancer receiving platinum-based chemotherapy[J]. Int J Clin Exp Pathol, 2015, 8(11):15065-15071.
[8] Huang J, Hu H, Xie Y, et al. Effect of TUBB3, TS and ERCC1 mRNA expression on chemoresponse and clinical outcome of advanced gastric cancer by multiplex branchedDNA liquid chip technology[J]. Zhong Nan Da Xue Xue Bao Yi Xue Ban, 2013, 38(6):582-589.
[9]黄朝晖,华东,李莉华,等. ERCC1 mRNA表达及基因多态性对胃癌辅助化疗预后的影响[J].南京医科大学学报(自然科学版), 2008, 28(4):453-456.
[10]胡传朋,顾康生. ERCC1蛋白表达在晚期胃癌含铂一线及替吉奥维持治疗中的作用[J].安徽医科大学学报,2016, 51(10):1504-1508.
[11]樊青霞,邢国臣,吴欣爱,等.化疗前食管癌组织中ERCC1 mRNA检测对化疗疗效的预测价值[J].郑州大学学报(医学版), 2005, 40(1):65-67.
[12]周健,吴列. ERCC1蛋白表达及其基因多态性与食管鳞状上皮细胞癌患者生存期关系[J].中国公共卫生, 2016,32(10):1418-1421.
[13] Geva R, Shamai S, Brazowsky E, et al. The predictive role of ERCC1 status in oxaliplatin based neoadjuvant therapy for metastatic colorectal cancer(mCRC)to the liver[J].Cancer Invest, 2015, 33(4):89-97.
[14]李兴普. ERCC1和XRCC1 SNP与结直肠癌易感性、药物敏感性及预后分析[D].泸州:四川医科大学, 2015.
[15]苏国兰. ERCC1蛋白在非霍奇金淋巴瘤组织中的表达及其临床意义[D].南宁:广西医科大学, 2011.
[16]许英君,刘艳艳,姚志华,等. ercc1、rrm1基因在侵袭性非霍奇金淋巴瘤中的表达及临床意义[J].肿瘤防治研究,2013, 40(5):451-454.
[17]王思力,李悦玮,许现辉,等.儿童急性淋巴细胞白血病ERCC1基因多态性分析[J].吉林大学学报(医学版),2007, 33(4):730-733.
[18] Doherty JA, Weiss NS, Fish S, et al. Polymorphisms in nucleotide excision repair genes and endometrial cancer risk[J]. Cancer Epidemiol Biomarkers Prev, 2011, 20(9):1873-1882.
[19] Palomba G, Atzori F, Budroni M, et al. ERCC1 polymorphisms as prognostic markers in T4 breast cancer patients treated with platinum-based chemotherapy[J]. J Transl Med, 2014, 12:272.
[20]齐冰丽,李琰,王娜,等. ERCC1基因多态性与卵巢上皮性癌患者铂类药物化疗敏感性及预后的关系[J].中华妇产科杂志, 2013, 48(11):847-852.
[21]蒋胜,李力,张玮,等. ERCC1基因mRNA表达水平在卵巢上皮性癌组织中的意义[J].实用妇产科杂志, 2009, 25(11):661-663.
[22]田美玲. ERCC1基因多态性及蛋白表达与上皮性卵巢癌铂类化疗敏感性及预后关系的研究[D].石家庄:河北医科大学, 2015.
[23] Cubukcu E, Fatih Olmez O, Saraydaroglu O, et al. Immunohistochemical expression of excision repair cross-complementing 1(ERCC1)in non-small-cell lung cancer:implications for patient outcome[J]. Clin Transl Oncol, 2011,13(11):826-830.
[24]高志强,韩宝惠,沈策,等. ERCC1蛋白检测指导晚期非小细胞肺癌个体化治疗的临床研究[J].中国癌症杂志,2013, 23(5):328-333.
[25] Lee SY, Hong MJ, Jeon HS, et al. Functional intronic ERCC1 polymorphism from regulomeDB can predict survival in lung cancer after surgery[J]. oncotarget, 2015, 6(27):24522-24532.
[26] Takenaka T, Yano T, Kiyohara C, et al. Effects of excision repair cross-complementation group 1(ERCC1)single nucleotide polymorphisms on the prognosis of non-small cell lung cancer patients[J]. Lung Cancer, 2010, 67(1):101-107.
[27] Wei HB, Hu J, Shang LH, et al. A meta-analytic review of ERCC1/MDR polymorphism and chemosensitivity to platinum in patients cell lung cancer1 with advanced nonsmall cell lung cancer[J]. Chin Med J(Engl), 2012, 125(16):2902-2907.
[28]庄琰,张中冕,程留奇. APE1和ERCC1基因多态性和肺腺癌易感性关系研究[J].医药论坛杂志, 2014, 35(5):4-6.
[29]田声望,李惠,谢玲,等.肺癌ERCC1调控区基因多态性与mRNA定量表达关联分析[J].临床肿瘤学杂志, 2009,14(12):1073-1076.
[30] De Castro G Jr, Pasini FS, Siqueira SA, et al. ERCC1 protein, mRNA expression and T19007C polymorphism as prognostic markers in head and neck squamous cell carcinoma patients treated with surgery and adjuvant cisplatinbased chemoradiation[J]. Oncol Rep, 2011, 25(3):693-699.
[31] Gao R, Reece KM, Sissung T. Are race-specific ERCC1haplotypes in melanoma cases versus controls related to the predictive and prognostic value of ERCC1 N118N?[J].BMJ Open, 2013, 3(1):1-7.
[32] Sun Y, Wu Y, Li W, et al. Genetic polymorphisms in nucleotide excision repair pathway influences response to chemotherapy and overall survival in osteosarcoma[J]. Int J Clin Exp Pathol, 2015, 8(7):7905-7912.
[33] Deng XD, Gao Q, Zhang W, et al. The age-related expression decline of ERCC1 and XPF for forensic age estimation:a preliminary study[J]. J Forensic Leg Med, 2017,49:15-19.